Analyst Ratings For Intercept Pharmaceuticals (NASDAQ:ICPT)
Today, Robert W. Baird reiterated its Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target of $253.00.
Some recent analyst ratings include
- 1/25/2018-Robert W. Baird Reiterated Rating of Outperform.
- 1/5/2018-Wedbush Reiterated Rating of Buy.
- 12/12/2017-Deutsche Bank initiated coverage with a Buy rating.
- 11/28/2017-Leerink Swann Reiterated Rating of Hold.
- 11/1/2017-Needham & Company LLC Reiterated Rating of Hold.
Recent Insider Trading Activity For Intercept Pharmaceuticals (NASDAQ:ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) has insider ownership of 9.20% and institutional ownership of 73.78%.
- On 10/2/2017 David Shapiro, CMO, sold 349 with an average share price of $58.90 per share and the total transaction amounting to $20,556.10.
- On 10/2/2017 Mark Pruzanski, CEO, sold 1,532 with an average share price of $58.87 per share and the total transaction amounting to $90,188.84.
- On 10/2/2017 Rachel Mcminn, Insider, sold 283 with an average share price of $58.89 per share and the total transaction amounting to $16,665.87.
- On 10/2/2017 Richard J Kim, SVP, sold 48 with an average share price of $58.10 per share and the total transaction amounting to $2,788.80.
- On 10/2/2017 Sandip Kapadia, CFO, sold 354 with an average share price of $58.83 per share and the total transaction amounting to $20,825.82.
- On 9/1/2017 David Shapiro, CMO, sold 1,250 with an average share price of $117.43 per share and the total transaction amounting to $146,787.50.
- On 8/25/2017 Lisa Bright, Insider, sold 253 with an average share price of $111.31 per share and the total transaction amounting to $28,161.43.
Recent Trading Activity for Intercept Pharmaceuticals (NASDAQ:ICPT)
Shares of Intercept Pharmaceuticals closed the previous trading session at 60.80 down -1.13 1.82% with 62.0 shares trading hands.